Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Solución terapéutica basada en células para tratamiento local con proteínas terapéuticas

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOSI20170126001
Publicado:
29/05/2017
Caducidad:
29/05/2018
Resumen:
Un instituto de investigación esloveno ha desarrollado y solicitado la patente de una solución terapéutica que incluye células que secretan una combinación de proteínas terapéuticas para el tratamiento de enfermedades y lesiones. Esta tecnología es más segura y efectiva que otras tecnologías similares que contienen células madre. Las células se colocan en un contenedor para el intercambio de nutrientes y proteínas terapéuticas. La tecnología se encuentra en fase preclínica para el tratamiento de heridas crónicas (por ejemplo, úlceras de pie diabético). El instituto busca pymes, grandes empresas y multinacionales con el fin de establecer acuerdos de comercialización con asistencia técnica o licencia.

Details

Tittle:
Cell-based therapeutic solution for local treatment with therapeutic proteins
Summary:
A Slovenian research institute has invented a therapeutic solution comprising cells secreting a combination of therapeutic proteins for the treatment of diseases and injuries. Its main advantage is that it is safer and more effective than similar technological solutions containing stem cells. The technology is at a preclinical stage. The institute is looking for SMEs, big companies and multinationals and offers commercial agency agreement with technical assistance or licence agreement.
Description:
The institute was established in 1946 in Ljubljana (Slovenia) and has nowadays more than 250 researchers. The institute conducts basic and applied research in the fields of biotechnology, environmental protection, chemistry, materials research, and chemical engineering.

By many human diseases, conditions and as a consequence of treatments the normal wound healing process is disrupted resulting in a chronic wound. Advanced treatments of such wounds include hyperbaric oxygen therapy, advanced wound dressings, growth factor treatment such as the use of Regranex (PDGF) and application of designed cellular products such as Apligraft and Dermagraft. Individual growth factors have been tested for treatment of various diseases and injuries of humans and animals such as treatment of diabetic foot ulcers, venous foot ulcers and pediatric burns. In the natural regenerative processes or in therapy by stem cells a combination of trophic factors is secreted providing the best therapy, which could be reproduced by the use of multiple growth factors. There are number of filed patents and undergoing clinical trials to identify growth factors and other soluble molecules to improve existing therapies.

Due to the aging population in developed countries regenerative medicine is struggling with enormous problems. Chronic wounds usually accompany other medical conditions and have thus long been neglected as a major health problem. Chronic wounds affect about 6.5 million people in the US alone, while it is estimated that 1-2% of population in developed countries will suffer from chronic wounds at least once in a life-time.

Stem cells are one of the most promising approaches to regenerative medicine therapy. But there are several problems associated with use of stem cells, such as low yield and high cost of isolation, potential for the development of cancer, uncontrollable spread and behaviour upon introduction into the body, which poses safety and efficiency questions.

Current therapeutic settings using trophic factors rely predominantly on a single soluble factor, while the Slovenian institute proposes that effective treatment should make use of the synergistic effect of several different soluble factors. The institute´s solution with encapsulated engineered cells would mimic the therapeutic effect of stem cells on the injured tissue. At the site of injury these engineered cells are programmed to secrete therapeutic soluble factors. This solution is expected to be safer, more controllable, affordable and yet individualized.

The offered technology works on the principal of cell therapy. The cells are located in a container which enables the exchange of nutrients and therapeutic proteins. The cells producing therapeutic proteins are present in the device in ratios and/or show expression and secretion of the therapeutic proteins which are appropriate for therapeutic application.

The offered technology solution is currently in preclinical stage for treatment of chronic wounds (e.g. diabetic foot ulcers) and the patent application was filed, but not yet granted.

Commecial agreement with technical assistance or licence agreement is offered to the interested companies.

The institute selected commecial agreement with technical assistance with the aim to sell the developed technology to big or multinational industrial companies that are able to further invest in industrialisation and commercialisation of the therapeutic solution. The institute selected licence agreement to offer the developed technology to a licensee (SMEs or big companies) that is interested to further exploit the technology and pay a licence fee.
Advantages and Innovations:
- Safer and more effective than similar technologies containing stem cells
- Safe and controllable cell solution, since cells are confined to an immunoisolatory container that allows for the exchange of nutrients and therapeutic proteins with the surrounding tissue
- More controllable, since the technology uses established and validated cell lines that secrete defined amounts of therapeutic proteins
- Affordable, since the cell lines can be produced on a large scale for all patients i.e. it does not require the isolation of a patient´s own cells
- Personalized and applicable to different medical conditions, since the content of the solution offered can be easily customized to suit an individual person´s needs and/or specific conditions.
Stage of Development:
Prototype available for demonstration
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
The offered technology solution is currently in preclinical stage for treatment of chronic wounds (e.g. diabetic foot ulcers) and the PCT patent application was filed, but not yet granted. The patent application is targeting the biggest markets like USA, Canada, China, Russia and EU.

Partner sought

Type and Role of Partner Sought:
The institute is looking for SMEs or big, multinational companies active in medical health care and wound-healing solutions sector intersted to buy or to licence the offered technology (patent pending).

Their role would be to buy the patented rights of the offered technology solution and further develop and commercially exploit it or to accomplish a licence agreement under which the industrial partner can exploit the offered technology and pay royalties for its use.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Keywords

Technology Keywords:
06001021 Productos de un único uso y bienes de consumo
06001015 Productos farmacéuticos / medicamentos
06001019 Tecnologías de células madre